The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
The DOI matches its Crossref record.
Abstract
BACKGROUND: Approximately 50% of patients diagnosed with major depressive disorder will experience a recurrent or chronic course of illness for which long-term treatment is recommended. Moreover, at least 20% of patients diagnosed with depression do not respond satisfactorily to several traditional antidepressant medication treatment trials. Very little is known about the health care costs of patients with treatment-resistant depression. METHOD: Based on medical claims data (MarketScan Research Database, The MEDSTAT Group, Cambridge, Mass.) from January 1, 1995, to June 30, 2000, a naturalistic, retrospective analysis was conducted to study the characteristics and health care utilization of patients with treatment-resistant depression. All patients having an International Classification of Diseases, Ninth Revision (ICD-9), diagnosis code for unipolar or bipolar depression with specified antidepressant dosing and treatment durations were initially selected. Patients were then classified as "treatment resistant" if either they switched from or augmented initial antidepressant medication with other antidepressants at least twice (outpatient treatment-resistant group) or they switched from or augmented their initial antidepressant medication and also had a claim for either a depression-related hospitalization or suicide attempt (hospitalized treatment-resistant group). Those meeting the initial medication and diagnosis selection criteria but not meeting the treatment-resistance criteria constituted the comparison group. Members of the comparison group had comparatively stable antidepressant medication use patterns, consistent with an acceptable response to treatment. Patients were followed for a minimum of 9 months. Resource utilization was calculated from index date to last available claims data point and then annualized. RESULTS: Treatment-resistant patients were more likely to be diagnosed with bipolar disorder or concurrent substance abuse or anxiety disorders than the comparison group (p <.001). Treatment-resistant patients were at least twice as likely to be hospitalized (general medical and depression related) and had at least 12% more outpatient visits (p <.02). Treatment resistance was also associated with use of 1.4 to 3 times more psychotropic medications (including antidepressants) (p <.001). Patients in the hospitalized treatment-resistant group had over 6 times the mean total medical costs of non-treatment-resistant depressed patients ($42,344 vs. $6512) (p <.001) and their total depression-related costs were 19 times greater than those of patients in the comparison group ($28,001 vs. $1455) (p <.001). CONCLUSION: Treatment-resistant depression is costly and associated with extensive use of depression-related and general medical services. These findings underscore the need for early identification and effective long-term maintenance treatment for treatment-resistant depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, for approximately 50% of those who suffer from depression, their illness will follow a chronic, relapsing course associated with considerable disability and impairment (Crown 2002).”
From Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents (2012) · cites this paper as Crown 2002
In the citing paper
“Direct medical costs associated with TRD are estimated to be 2-6 times higher compared with other patients with MDD, 42, 43 with costs increasing with chronicity and severity of TRD. 44”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
In the citing paper
“Patients with TRD are twice as likely to be hospitalised compared with non-TRD patients, and require increased numbers of psychiatric outpatient visits. 43”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [43]
Citations
Cites
Still being checked.
Cited by
Shippee, N. D., Shah, N. D., May, C. R., Mair, F. S., & Montori, V. M. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.05.005 · Cited by 728
Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Unipolar and Bipolar Depression
Holtzheimer, P. E. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1456 · Cited by 608
“Patients were taking a mean (SD) of 3(2) psychotropic medications at the time of surgery.”
BackgroundMethodMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
(2007) · PubMed · Cited by 453
Defining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
Metadata
- Authors
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-11-15
- Volume
- 63
- Issue
- 11
- Pages
- 963-971
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2098750661
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 13 · 2023: 23 · 2022: 20 · 2021: 17 · 2020: 17 · 2019: 18 · 2018: 16 · 2017: 9 · 2016: 15 · 2015: 17 · 2014: 19 · 2013: 19 · 2012: 17
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- treatment-resistant depression, major depressive disorder, bipolar disorder, health care utilization, health care costs, antidepressants, hospitalization, psychotropic drug use, substance use comorbidity, anxiety disorders, health insurance claims data, suicide attempts, outpatient visits, chronic depression, recurrent depression
- MeSH terms
- Adult, Ambulatory Care, Bipolar Disorder, Costs and Cost Analysis, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Patient Admission, Psychotropic Drugs, Referral and Consultation, Retrospective Studies, Utilization Review, Comorbidity, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. https://app.cochat.ai/papers/10.4088/jcp.v63n1102
- The paper
- Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002). The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v63n1102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.